Press Releases
At Pulmatrix, we are committed to communicating clear and consistent information. Here we feature current and historic content concerning our science, our pipeline, and our corporate initiatives and achievements. Please check in often for the most recent press releases and information.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
- Jul 19, 2016Data Support Continued Development Towards Pivotal Bioequivalence Program for European Registration
Pulmatrix, Inc. (NASDAQ: PULM), today announced positive topline data from a Phase 1 pilot pharmacokinetic bioavailability trial of PUR0200. PUR0200 is a novel dry powder formulation of a...
- Jul 6, 2016In an interview with News Medical, Pulmatrix CEO Robert Clarke explains how innovative dry powders enable drugs to be delivered to the lungs more efficiently
Pulmatrix, Inc. (NASDAQ: PULM), a pharmaceutical company developing innovative inhaled drugs, today announced that Chief Executive Officer Robert Clarke, PhD, has described advances in inhaled...
- Jun 27, 2016
Pulmatrix, Inc., (NASDAQ: PULM), a pharmaceutical company developing innovative inhaled drugs today announced the release of an animated life sciences video [ir.pulmatrix.com] to raise awareness...
- Jun 24, 2016Inclusion in the index will bring greater shareholder awareness of Pulmatrix's progress in developing novel inhaled drugs
Pulmatrix, Inc., (NASDAQ: PULM), a specialty pharmaceutical company developing innovative inhaled drugs, announced today that it was added to the Russell Microcap Index when Russell Investments...
- May 25, 2016PUR0200, a once-daily long acting muscarinic antagonist bronchodilator formulation, was given to healthy volunteers to measure pharmacokinetics and to test for safety.
Pulmatrix (NASDAQ:PULM), a specialty pharmaceutical company developing novel inhaled therapeutic formulations based on the company's proprietary iSPERSE™ technology, has completed a pilot...
- May 24, 2016
Pulmatrix, Inc., (NASDAQ: PULM) today announced that its Chief Executive Officer, Robert Clarke, will present an overview of the company, its promising inhaled drug delivery technology, and its...
- May 5, 2016
Pulmatrix, Inc. (NASDAQ: PULM) today reports its first quarter financial results and provides an update on the progress of its drug development pipeline. "During the first quarter, we continued to...
- Apr 19, 2016Writing in ONdrugDelivery Magazine, CSO David L. Hava describes how innovative new strategies for delivering inhaled drugs to the lungs can fight serious bacterial and fungal infections.
Pulmatrix, Inc. (NASDAQ: PULM) announced today that its Chief Scientific Officer, David L. Hava, PhD, has written an article in ONdrugDelivery Magazine highlighting advances in delivering drugs to...
- Mar 10, 20162015 was a transformational year - lead assets for COPD and cystic fibrosis continue to progress in clinical development.
Pulmatrix, Inc. (NASDAQ: PULM) today announces 2015 financial results, reviews the Company's recent progress, and provides an outlook for 2016 for its pulmonary disease development pipeline. "2015...
-
Mar 10, 2016
Dear Fellow Shareholders, Continuing our Momentum As Pulmatrix moves into 2016, we wanted to describe to our shareholders the significant progress the Company is making—and how...
